New combo therapy targets Hard-to-Treat cancers
Disease control
Not yet recruiting
This early-phase study tests a new drug combination (L19IL2 plus ruxolitinib) in people with advanced kidney, pancreatic, or colorectal cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 partici…
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC